Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G.
O'Connor CM, et al.
Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20.
Oncogene. 2020.
PMID: 31541192
Free PMC article.